You are here: Industry Insights > Boehringer Ingelheim

News List

AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023 fiercepharma
December 05, 2018
AbbVie is on a hot streak striking patent deals to protect its top drug, Humira. Even as Boehringer Ingelheim has opted to fight the company’s patent claims in court
Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment pharmatimes
November 19, 2018
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, small molecule
Boehringer Ingelheim inaugurates new centre for agile working methods worldpharmanews
November 01, 2018
Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site.
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC worldpharmanews
September 28, 2018
The survey results will be presented as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada.
Boehringer Ingelheim exercises option to buy ViraTherapeutics, boosting viral-based approach to treating cancer biospectrumasia
September 14, 2018
Boehringer Ingelheim announced Thursday that it has acquired all shares of ViraTherapeutics for a total of 210 million euros ($244 million), with the price based on an option and share purchase agreement signed between the companies in 2016.
BI partners with Tsinghua for immuno therapies biospectrumasia
September 06, 2018
This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders (RBB) and Cancer Immunology and Immune Modulation Research Departments.
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease pharmatimes
July 16, 2018
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Boehringer Ingelheim acquires MabVax’s programme for solid tumours pharmaceutical-technology
July 12, 2018
Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target a glycan that is commonly overexpressed on various solid tumours cancers.
Highmark Announces Outcomes-Based Agreement with Boehringer Ingelheim for Jardiance americanpharmaceuticalreview
July 11, 2018
Highmark announced an outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes
Boehringer Ingelheim rolls-out COPD digital adherence programme pharmaphorum
April 28, 2018
Boehringer Ingelheim has expanded access to its digital adherence programme that helps COPD patients take their medicines as prescribed by offering educational and motivational tools.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page